SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Strategies & Market Trends : ajtj's Post-Lobotomy Market Charts and Thoughts
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
Recommended by:
Sun Tzu
The Ox
To: bull_dozer who wrote (70443)9/28/2022 12:05:31 AM
From: bull_dozer2 Recommendations  Read Replies (1) of 97611
 
Drugmakers Eisai and Biogen claim success in Alzheimer’s drug study

Eisai and Biogen said they would apply for regulatory approval for a new Alzheimer’s drug following the results of a late-stage clinical trial that showed it slowed the rate at which the disease progresses.
The companies said on Tuesday that the phase-three trial had demonstrated that giving lecanemab, a monoclonal antibody treatment, to patients in the early stages of the disease reduced the rate of cognitive decline by 27 per cent compared with participants who received a placebo.
The results from the clinical trial will provide hope to the roughly 50mn Alzheimer’s suffers worldwide that progress is being made in the search for treatments to slow the disease. It will also encourage Eli Lilly and Roche, which are conducting trials of similar drugs.
The drug co-developed by Eisai and Biogen reduced the build-up of sticky plaques in the brain known as beta amyloid, which are at the centre of an acrimonious scientific debate about what causes Alzheimer’s disease.
Scientists have tried for almost three decades to prove the so-called amyloid hypothesis, the idea that clumps of toxic amyloid cells that bind together in the brain is the primary cause of Alzheimer’s. But dozens of drug trials have failed to prove that clearing the plaques can slow the rate of cognitive decline, causing disappointment for sufferers and their families.
The botched launch last year of Biogen’s aducanumab — the first amyloid-clearing drug to win approval and the first new treatment for the disease in almost two decades — heightened doubts over the amyloid hypothesis.
However, Eisai said the positive results from one of the largest clinical trials of Alzheimer’s patients ever undertaken was a “milestone” and proved the amyloid hypothesis theory.

ft.com
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News